Neoadjuvant chemotherapy for breast cancer - background for the indication of locoregional treatment
Neoadjuvant chemotherapy (NACT) has been widely adopted into the multidisciplinary management of breast cancer. The prognostic impact of treatment response has been clearly demonstrated. However, the impact of treatment response on the indication for adjuvant radiotherapy is unclear. This review sum...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 July 2018
|
| In: |
Strahlentherapie und Onkologie
Year: 2018, Jahrgang: 194, Heft: 9, Pages: 797-805 |
| ISSN: | 1439-099X |
| DOI: | 10.1007/s00066-018-1329-8 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/s00066-018-1329-8
|
| Verfasserangaben: | David Krug, René Baumann, Wilfried Budach, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, Thomas Hehr, Marc D. Piroth, Felix Sedlmayer, Rainer Souchon, Frederik Wenz, Rolf Sauer, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) |
| Zusammenfassung: | Neoadjuvant chemotherapy (NACT) has been widely adopted into the multidisciplinary management of breast cancer. The prognostic impact of treatment response has been clearly demonstrated. However, the impact of treatment response on the indication for adjuvant radiotherapy is unclear. This review summarizes important implications of NACT and treatment response on the risk of recurrence and locoregional multidisciplinary management from the standpoint of radiation oncology. |
|---|---|
| Beschreibung: | Gesehen am 30.10.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1439-099X |
| DOI: | 10.1007/s00066-018-1329-8 |